Revance Therapeutics Inc

NASDAQ:RVNC   3:59:57 PM EDT
25.11
-0.18 (-0.71%)
Regulatory, Other Pre-Announcement

Revance Reports Positive Results from Trial in Cervical Dystonia

Published: 10/14/2020 12:13 GMT
Revance Therapeutics Inc (RVNC) - Revance Reports Positive Results From Aspen-1 Phase 3 Trial of Daxibotulinumtoxina for Injection in Cervical Dystonia.
Revance Therapeutics Inc - Trial Met Primary and All Secondary Endpoints for Both 125- and 250-unit Doses With High Statistical Significance.
Revance Therapeutics Inc - Drug Was Generally Safe and Well-tolerated at Both Doses, With an Encouraging Safety Profile.
Revance Therapeutics Inc - Expects Results From Companion Aspen-ols Phase 3 Trial in 2021.